TY - JOUR
T1 - Risk of thromboembolic events after percutaneous left atrial appendage ligation in patients with atrial fibrillation
T2 - Long-term results of a multicenter study
AU - Mohanty, Sanghamitra
AU - Gianni, Carola
AU - Trivedi, Chintan
AU - Gadiyaram, Varuna
AU - Della Rocca, Domenico Giovani
AU - MacDonald, Bryan
AU - Horton, Rodney
AU - Al-Ahmad, Amin
AU - Gibson, Douglas N.
AU - Price, Matthew
AU - Krumerman, Andrew K.
AU - Palma, Eugen C.
AU - Di Biase, Luigi
AU - Lakkireddy, Dhanunjaya
AU - Natale, Andrea
N1 - Publisher Copyright:
© 2019 Heart Rhythm Society
PY - 2020/2
Y1 - 2020/2
N2 - Background: Percutaneous left atrial appendage (LAA) occlusion with Lariat has emerged as a viable alternative to oral anticoagulation (OAC) to prevent thromboembolic (TE) events in patients with atrial fibrillation. Objective: We evaluated the long-term TE risk in post-Lariat patients. Methods: Consecutive patients undergoing LAA ligation with the Lariat device at multiple centers with at least 1-year follow-up were included in the analysis. Transesophageal echocardiography (TEE) was performed at 4 weeks, 6 months, and 12 months to assess the completeness of LAA occlusion. OAC was discontinued if 4-week TEE revealed no device-related thrombus and complete closure of the appendage. Patients remained on 81 mg of aspirin per day after discontinuation of the blood thinner. Results: A total of 306 patients were included in the study (mean age 68.8 ± 11.0 years; mean CHA2DS2-VASc score 3.6 ± 1.7). Four-week TEE revealed leaks in 81 patients (26.5%); all leaks were less than 5 mm in diameter. At 6-month TEE, spontaneous closure of the leak was demonstrated in 21 patients (25.9%), 26 patients (32%) underwent a successful leak closure procedure, and the remaining 34 (42%) patients were placed on OAC. At the median follow-up period of 15.9 ± 9.2 months, 9 TE events (2.9%) were reported: 7 with persistent leak and 2 without any detectable leaks on 2-dimensional TEE (P < .001). Conclusion: Complete occlusion of the LAA with the Lariat device was associated with the low rate of TE events at long-term follow-up. However, residual leaks were common after Lariat closure and the stroke rate was significantly higher in patients with incomplete occlusion, even with small leaks.
AB - Background: Percutaneous left atrial appendage (LAA) occlusion with Lariat has emerged as a viable alternative to oral anticoagulation (OAC) to prevent thromboembolic (TE) events in patients with atrial fibrillation. Objective: We evaluated the long-term TE risk in post-Lariat patients. Methods: Consecutive patients undergoing LAA ligation with the Lariat device at multiple centers with at least 1-year follow-up were included in the analysis. Transesophageal echocardiography (TEE) was performed at 4 weeks, 6 months, and 12 months to assess the completeness of LAA occlusion. OAC was discontinued if 4-week TEE revealed no device-related thrombus and complete closure of the appendage. Patients remained on 81 mg of aspirin per day after discontinuation of the blood thinner. Results: A total of 306 patients were included in the study (mean age 68.8 ± 11.0 years; mean CHA2DS2-VASc score 3.6 ± 1.7). Four-week TEE revealed leaks in 81 patients (26.5%); all leaks were less than 5 mm in diameter. At 6-month TEE, spontaneous closure of the leak was demonstrated in 21 patients (25.9%), 26 patients (32%) underwent a successful leak closure procedure, and the remaining 34 (42%) patients were placed on OAC. At the median follow-up period of 15.9 ± 9.2 months, 9 TE events (2.9%) were reported: 7 with persistent leak and 2 without any detectable leaks on 2-dimensional TEE (P < .001). Conclusion: Complete occlusion of the LAA with the Lariat device was associated with the low rate of TE events at long-term follow-up. However, residual leaks were common after Lariat closure and the stroke rate was significantly higher in patients with incomplete occlusion, even with small leaks.
KW - Lariat
KW - Leak
KW - Left atrial appendage
KW - Oral anticoagulation
KW - TE risk
UR - http://www.scopus.com/inward/record.url?scp=85073729842&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073729842&partnerID=8YFLogxK
U2 - 10.1016/j.hrthm.2019.08.003
DO - 10.1016/j.hrthm.2019.08.003
M3 - Article
C2 - 31400519
AN - SCOPUS:85073729842
SN - 1547-5271
VL - 17
SP - 175
EP - 181
JO - Heart Rhythm
JF - Heart Rhythm
IS - 2
ER -